Business
Sobi Licenses Innate’s Skin-Lymphoma Drug in a Deal Worth Up to $580M
Sobi gains commercial rights to lacutamab, a first-in-class antibody for cutaneous T-cell lymphoma now in a Phase 3 confirmatory trial and heading for accelerated approval.